This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
LEHI, Utah–(BUSINESS WIRE)–Mar 20, 2019–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced that it has signed a Memorandum of Understanding (MOU) with NewPath Health Care Solutions, Inc. of Ontario, Canada; Mercator Biologic, Inc. of Centerville, Utah; and True DNA Story, LLC of Centerville, Utah. The purpose of the MOU is to strategically explore the full capabilities of each company to identify synergies and opportunities in order to leverage the unique skillsets of the collective.
The intention of the MOU is to build a cooperative venture capable of leveraging the strengths of each company to enhance and further the science of genetics, markets and potential clients’ quality of life. It also includes mutual cooperation in expanding and improving on the established product portfolios and future plans.
“The four companies that are a part of the agreement have each developed technologies, methodologies, processes and solutions that are unique and powerful and lend themselves to game-changing collaborations and innovations,” said Ian Jenkins, CEO of Frelii Inc. “Frelii will offer its highly advanced artificial-intelligence-based technology platform to the group, and also benefit from their technology and expertise to further our corporate growth and market objectives. By working together, we will collectively continue to outpace competitors and more rapidly advance the science and real-world practicality of leveraging genetic data for the good of humanity.”
The parties in the MOU also have agreed that there is an opportunity to participate in a pilot research initiative which is of mutual interest and may present an opportunity for each entity to validate its technology and provide a means to significantly advance each other’s commercial capabilities. If enacted, this initiative will be finalized in a statement of work that will define the phases of the initiative and the roles of each participant.
About Frelii Inc.
Frelii Inc. is a medical technology company that uses gene sequencing and artificial intelligence to determine risk and lifestyle modifications. Its technology analyzes the most comprehensive markers (60,000,000+) on the market to date. Frelii’s technology generates accurate and profoundly valuable insight into DNA. It opens opportunities never before realized in health care, precision medicine, insurance, corporate wellness as well as personal health and risk identification. For more information, please visit www.frelii.com. Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.
Follow Frelii online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/
Safe Harbor Statement:
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190320005857/en/
CONTACT: Media Contact:
KEYWORD: UNITED STATES NORTH AMERICA UTAH
INDUSTRY KEYWORD: HEALTH GENETICS RESEARCH SCIENCE
SOURCE: Frelii Inc.
Copyright Business Wire 2019.
PUB: 03/20/2019 07:39 PM/DISC: 03/20/2019 07:39 PM